Chancellor Donald, MD
Hematology & Oncology · Lafayette, LANPI 1487690376
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,585 of the $9,689 with a category attached, or 78.3%. 18 manufacturers reported payments, led by Pfizer at 59.5% of the total. Reporting peaked in 2019 at $6,115 and has fallen 70.1% since, to $1,831 in 2025.
Across 44 payments — averaging $220.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$6K
- AstraZeneca$3K
- Lilly USA, LLC$172
- Eisai Inc.$154
- Astellas Pharma US Inc$96
- E.r. Squibb & Sons, L.L.C.$77
- plus $265 from 12 others
Across 18 payments — averaging $2791.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$45K
- Global Blood Therapeutics, Inc.$5K
What the payments were for
- Consulting fees$7,58578%
- Travel & lodging$6377%
- Food & beverage$1,36014%
- Education$1061%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 11 | $5,769 |
| AstraZeneca(2 entities) | 6 | $3,156 |
| Lilly USA, LLC | 2 | $172 |
| Eisai Inc. | 3 | $154 |
| Astellas Pharma US Inc | 4 | $96 |
| E.r. Squibb & Sons, L.L.C. | 3 | $77 |
| Merck | 3 | $48 |
| Novartis | 2 | $36 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $29 |
| Emmaus Medical, Inc. | 1 | $24 |
| Amgen | 1 | $21 |
| Bayer | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Stemline Therapeutics Inc. | 1 | $17 |
| Lexicon Pharmaceuticals, Inc. | 1 | $14 |
| Partner Therapeutics, Inc. | 1 | $14 |
| Gilead | 1 | $12 |
| Tesaro, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,689 in reported general payments places this provider in the 65th percentile of 183 hematology & oncology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NinlaroIxazomib Citrate | 12 | $149,979 |
| EliquisApixaban | 30 | $20,569 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 16 | $321 |
| Morphine Sulfate ErMorphine Sulfate | 12 | $227 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $19 | $149,97912 claims |
| PfizerEliquis | $5,769 | $20,56930 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 183 hematology & oncology providers in Louisiana.
Other hematology & oncology in Lafayette
- Victoria Panelli-RameryLafayette$13K
- Sudhir AggarwalLafayette$12K
- Molly ThomasLafayette$12K
- Hana SafahBaton Rouge$2M
- Pedro BarataNew Orleans$928K
- Maissaa JanbainNew Orleans$862K
- Nakhle SabaBaton Rouge$842K
- Marc MatranaNew Orleans$757K
- Prakash PeddiShreveport$405K
- Sanjay JunejaBaton Rouge$346K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.